Treating patients with severe sepsis

New England Journal of Medicine

Volumn 340, Issue 3, 1999, Pages 207-214

  Wheeler, Arthur P ^b   Bernard, Gordon R ^a  

^a T 1208 Medical Center No   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTIOXIDANT; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRADYKININ ANTAGONIST; DOBUTAMINE; DOPAMINE; ENDOTOXIN ANTIBODY; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; PHENYLEPHRINE; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOXANE RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIMICROBIAL THERAPY; ARTIFICIAL VENTILATION; BLOOD CLOTTING DISORDER; CARDIOGENIC SHOCK; DIGESTIVE SYSTEM FUNCTION DISORDER; HUMAN; INFLAMMATION; MICROBIOLOGY; MULTIPLE ORGAN FAILURE; NEUROLOGIC DISEASE; NUTRITIONAL SUPPORT; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SEPSIS;

ANTI-BACTERIAL AGENTS; HUMANS; MULTIPLE ORGAN FAILURE; NUTRITION PHYSIOLOGY; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; SEPSIS; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS;

EID: 0033590515     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199901213400307     Document Type: Review

References (90)

1. Bone RC, Balk RA, Cerra FB, et al. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-55.
2. Increase in National Hospital Discharge Survey rates for septicemia - United States, 1979-1987. MMWRMorb Mortal Wkly Rep 1990;39: 31-4.
3. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995;273:117-23.
4. Milberg JA, Davis DR, Steinberg KP, Hudson LD. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 1995;273:306-9.
5. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. Crit Care Med 1989;17:389-93.
6. Parillo JE, moderator. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990;113:227-42.
7. Bernard GR. Sepsis trials: intersection of investigation, regulation, funding, and practice. Am J Respir Crit Care Med 1995;152:4-10.
8. Christman JW, Wheeler AP, Bernard GR. Cytokines and sepsis: what are the therapeutic implications? J Intensive Care 1991;6:172-82.
9. Strieter RM, Kunkel SL. Acute lung injury: the role of cytokines in the elicitation of neutrophils. J Investig Med 1994;42:640-51.
10. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318:1481-6.
11. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-101.
12. Sessler CN, Windsor AC, Schwartz M, et al. Circulating ICAM-I is increased in septic shock. Am J Respir Crit Care Med 1995;151:1420-7
13. Wheeler AP, Hardie WD, Bernard GR. The role of cyclooxygenase products in lung injury induced by tumor necrosis factor in sheep. Am Rev Respir Dis 1992;145:632-9.
14. van der Poll T, Büller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622-7.
15. Waage A, Espevik T. Interleukin 1 potentiates the lethal effect of tumor necrosis factor α/cachectin in mice. J Exp Med 1988;167:1987-92.
16. Herbertson MJ, Werner HA, Goddard CM, et al. Anti-tumor necrosis factor-alpha prevents decreased ventricular contractility in endotoxemic pigs. Am J Respir Crit Care Med 1995;152:480-8.
17. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-71.
18. Schlag G, Redl H, Davies J, Haller I. Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model. Shock 1994; 2:10-8.
19. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokincs - CXC and CC chemokines. Adv Immunol 1994;55:97-179.
20. Many C, Misset B, Tamion F, Fitting C, Carlet J, Cavaillon JM. Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and nonseptic origin Crit Care Med 1994;22:673-9.
21. Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized, controlled trial of IL-10 in humans: inhibition of inflammatory cytokine production and immune responses. J Immunol 1995;154:5492-9.
22. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNE Blood 1990;75:40-7.
23. Fekade D, Knox K, Hussein K, et al. Prevention of Jarish-Herxheimer reactions by treatment with antibodies against tumor necrosis factor α. N Engl J Med 1996;335:311-5.
24. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997;25:1095-100.
25. Bernard GR, Reines HD, Halushka PV, et al. Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome: effects of cyclooxygenase inhibition. Am Rev Respir Dis 1991;144:1095-101.
26. Bernard GR, Wheeler AP, Russell JA, et al. Effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997; 336:912-8.
27. Kieft H, Hoepelman AIM, Zhou W, Rozenberg Arska M, Struyvenberg A, Verhoef J. The sepsis syndrome in a Dutch university hospital: clinical observations. Arch Intern Med 1993;153:2241-7.
28. Reinhart K, Wiegand-Lohnen C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996;24:733-42. [Erratum, Crit Care Med 1996;24:1608.]
29. Pittet D, Thievent B, Wenzel RP, Li N, Auckenthaler R, Suter PM. Bedside prediction of mortality from bacteremic sepsis: a dynamic analysis of ICU patients. Am J Respir Crit Care Med 1996;153:684-93.
30. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996; 334:1698-702.
31. Darby JM, Linden P, Pasculle W, Saul M. Utilization and diagnostic yield of blood cultures in a surgical intensive care unit. Crit Care Med 1997;25:989-94.
32. Washington JA II, Ilstrup DM. Blood cultures: issues and controversies. Rev Infect Dis 1986;8:792-802.
33. Opal SM, Fisher CJ Jr, Dhainaut JFA, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997;25: 1115-24.
34. Fein AM, Bernard GR, Criner GJ, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127): results of a randomized, double-blind, placebo-controlled trial: CP-0127 SIRS and Sepsis Study Group. JAMA 1997; 277:482-7.
35. Weinstein M, Murphy J, Reller LB, Lichtenstein KA. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis. Rev Infect Dis 1983;5: 54-70.
36. Natanson C, Danner RL, Reilly JM, et al. Antibiotics versus cardiovascular support in a canine model of human septic shock. Am J Physiol 1990;259:H1440-H1447.
37. Shcncp JL, Morgan KA. Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis 1984;150:380-8.
38. Horn DL, Opal SM, Lomastro E. Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in gram-negative sepsis. Scand J Infect Dis Suppl 1996;101:9-13.
39. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-53.
40. Hebert PC, Drummond AJ, Singer J, Bernard GR, Russell JA. A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome. Chest 1993;104:230-5.
41. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991;324:429-36.
42. The National Committee for the Evaluation of Centoxin. The French National Registry of HA-IA (Centoxin) in septic shock: a cohort study of 600 patients. Arch Intern Med 1994;154:2484-91.
43. Wheeler A, Carmichael L, Christman B, et al. Renal function abnormalities in sepsis. Am J Respir Crit Care Med 1995;151:Suppl:A317. abstract.
44. Bone RC, Maunder R, Slotman G, et al. An early test of survival in patients with the adult respiratory distress syndrome: the PaO2/FIO2 ratio and its differential response to conventional therapy. Chest 1989;96:849-51.
45. Field S, Kelly SM, Macklem PT. The oxygen cost of breathing in patients with cardiorespiratory disease. Am Rev Respir Dis 1982;126:9-13.
46. Wheeler AP, Christman B, Swindell B, et al. Lung dysfunction in sepsis: impact of ibuprofen. Am J Respir Crit Care Med 1998;157:Suppl:A115. abstract.
47. Wright PH, Carmichael LC, Bernard GR. Effect of bronchodilators on lung mechanics in the acute respiratory distress syndrome (ARDS). Chest 1994;106:1517-23.
48. Wheeler AP, Carroll FE, Bernard GR. Radiographic issues in adult respiratory distress syndrome. New Horiz 1993;1:471-7.
49. McHugh LG, Milberg JA, Whitcomb ME, Schoene RB, Maunder RJ, Hudson LD. Recovery of function in survivors of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1994;150:90-4.
50. Tobin MJ. Mechanical ventilation. N Engl J Med 1994;330:1056-61.
51. Roupie E, Dambrosio M, Servillo G, et al. Titration of tidal volume and induced hypercapnia in acute respiratory distress syndrome. Am J Respir Crit Care Med 1995;152:121-8.
52. Hickling KG, Henderson SJ, Jackson R. Low mortality associated with low volume pressure limited ventilation with permissive hypercapnia in severe adult respiratory distress syndrome. Intensive Care Med 1990;16: 372-7.
53. Amato MBP, Barbas CSV, Medeiros DM, et al. Beneficial effects of the "open lung approach" with low distending pressures in acute respiratory distress syndrome: a prospective randomized study on mechanical ventilation. Am J Respir Crit Care Med 1995;152:1835-46.
54. Carmichael LC, Dornisky PM, Higgins SB, et al. Diagnosis and therapy of acute respiratory distress syndrome in adults: an international survey. J Crit Care 1996;11:9-18.
55. Bernard GR, Luce JM, Sprung CL, et al. High dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987;317:1565-70.
56. Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;153:991-6.
57. Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyelin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996;154:1671-7.
58. Bone RC, Slotman G, Maunder R, et al. Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Chest 1989;96:114-9.
59. Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996;334:1417-21.
60. Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest 1997;112:164-72.
61. Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 1993;21:1635-42.
62. Pulmonary Artery Catheter Consensus Conference: consensus statement. Crit Care Med 1997;25:910-25.
63. Connors AF Jr, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 1996; 276:889-97.
64. Rackow EC, Falk JL, Fein IA, et al. Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med 1983;11:839-50.
65. Ledingham IM, McArdle CS. Prospective study of the treatment of septic shock. Lancet 1978;1:1194-7.
66. Newman M, Demling RH. Colloid vs. crystalloid: a current perspective. Int Crit Care Dig 1990;9:3-8.
67. Bunnell E, Parrillo JE. Cardiac dysfunction during septic shock. Clin Chest Med 1996;17:237-48.
68. Demon MD, Chcrtow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996;50:4-14.
69. Meadows D, Edwards JD, Wilkins RG, Nightingale P. Reversal of intractable septic shock with norepinephrine therapy. Crit Care Med 1988; 16:663-6.
70. Cooper DJ, Walley KR, Wiggs BR, Russell JA. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis: a prospective, controlled clinical study. Ann Intern Med 1990;112: 492-8.
71. Russell JA, Phang PT. The oxygen delivery/consumption controversy: approaches to management of the critically ill. Am J Respir Crit Care Med 1995;149:533-7.
72. Hayes MA, Timmins AC, Yau EHS, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994;330:1717-22.
73. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995;333:1025-32.
74. Marik PE, Mohedin M. The contrasting effects of dopaminc and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994;272:1354-7.
75. Pastor CM, Billiar TR, Losser MR, Payen DM. Liver injury during sepsis. J Crit Care 1995;10:183-97.
76. Cerra FB, Siegel JH, Coleman B, Border JR, McMenamy RR. Septic autocannibalism: a failure of exogenous nutritional support. Ann Surg 1980;192:570-80.
77. Moore FA, Feliciano DV, Andrassy RJ, et al. Early enteral feeding, compared with parenteral, reduces postoperative septic complications: the results of a meta-analysis. Ann Surg 1992;216:172-83.
78. Hadfield RJ, Sinclair DG, Houldsworth PE, Evans TW. Effects of enteral and parenteral nutrition on gut mucosal permeability in the critically ill. Am J Respir Crit Care Med 1995;152:1545-8.
79. Koretz RL. Nutritional supplementation in the ICU: how critical is nutrition for the critically ill? Am J Respir Crit Care Med 1995;151:570-3.
80. Cerra FB, Benitez MR, Blackburn GL, et al. Applied nutrition in ICU patients: a consensus statement of the American College of Chest Physicians. Chest 1997;111:769-78.
81. Hartman DL, Helterbrand JD, Bernard GR, Ibuprofen in Sepsis Group. Protein C (PC) levels in sepsis: association with mortality. Am J Respir Crit Care Med 1997;155:Suppl:A708. abstract.
82. Ten Cate H, Brandjes DPM, Wolters HJ, van Deventer SJH. Disseminated intravascular coagulation: pathophysiology, diagnosis, and treatment. New Horiz 1993;1:312-23.
83. Dhainaut J-F, Mira J-P, Fierobe L. Platelet activating factor: pathophysiological changes and therapeutic implications in sepsis. In: Reinhart K, Eyrich K, Sprung C, eds. Update in intensive care and emergency medicine. Vol. 18. Berlin, Germany: Springer-Verlag, 1994:397-413.
84. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101: 816-23.
85. Bastos PG, Sun X, Wagner DP, Wu AW, Knaus WA. Glasgow Coma Scale score in the evaluation of outcome in the intensive care unit: findings from the Acute Physiology and Chronic Health Evaluation III study. Crit Care Med 1993;21:1459-65.
86. Sprung CL, Peduzzi PN, Shatney CH, et al. Impact of encephalopathy on mortality in the sepsis syndrome. Crit Care Med 1990;18:801-6.
87. Marini JJ, Wright L. General supportive care of the critically ill patient. Semin Respir Crit Care Med 1997;18:3-17.
88. Wheeler AP. Analgesia, sedation, and therapeutic paralysis in the critically ill. Semin Respir Crit Care Med 1997;18:39-63.
89. Cook D. Prevention of stress ulcers and ventilator-associated pneumonia: examining the evidence. Semin Respir Crit Care Med 1997;18:91-5.
90. Jain M, Schmidt GA. Venous thromboembolism: prevention and prophylaxis. Semin Respir Crit Care Med 1997;18:79-90.